Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs

Yoshihiro Hayakawa, Manabu Kawada, Hiroyoshi Nishikawa, Takahiro Ochiya, Hideyuki Saya, Hiroyuki Seimiya, Ryoji Yao, Masahiro Hayashi, Chieko Kai, Akira Matsuda, Tomoki Naoe, Atsushi Ohtsu, Taku Okazaki, Hideo Saji, Masataka Sata, Haruhiko Sugimura, Yuichi Sugiyama, Masakazu Toi, Tatsuro Irimura

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Non-clinical studies are necessary at each stage of the development of oncology drugs. Many experimental cancer models have been developed to investigate carcinogenesis, cancer progression, metastasis, and other aspects in cancer biology and these models turned out to be useful in the efficacy evaluation and the safety prediction of oncology drugs. While the diversity and the degree of engagement in genetic changes in the initiation of cancer cell growth and progression are widely accepted, it has become increasingly clear that the roles of host cells, tissue microenvironment, and the immune system also play important roles in cancer. Therefore, the methods used to develop oncology drugs should continuously be revised based on the advances in our understanding of cancer. In this review, we extensively summarize the effective use of those models, their advantages and disadvantages, ranges to be evaluated and limitations of the models currently used for the development and for the evaluation of oncology drugs. This review summarizes the effective use of animal models, their advantages and disadvantages, ranges to be evaluated and limitations of the models currently used for the development and for the evaluation of oncology drugs.

Original languageEnglish
Pages (from-to)189-202
Number of pages14
JournalCancer Science
Volume107
Issue number2
DOIs
Publication statusPublished - 2016 Feb 1

Fingerprint

Drug Evaluation
Neoplasms
Pharmaceutical Preparations
Cellular Microenvironment
Immune System
Carcinogenesis
Theoretical Models
Animal Models
Neoplasm Metastasis
Safety
Growth

Keywords

  • Animal model
  • Cancer
  • Drug development
  • Oncology drug
  • Regulatory science

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hayakawa, Y., Kawada, M., Nishikawa, H., Ochiya, T., Saya, H., Seimiya, H., ... Irimura, T. (2016). Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs. Cancer Science, 107(2), 189-202. https://doi.org/10.1111/cas.12857

Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs. / Hayakawa, Yoshihiro; Kawada, Manabu; Nishikawa, Hiroyoshi; Ochiya, Takahiro; Saya, Hideyuki; Seimiya, Hiroyuki; Yao, Ryoji; Hayashi, Masahiro; Kai, Chieko; Matsuda, Akira; Naoe, Tomoki; Ohtsu, Atsushi; Okazaki, Taku; Saji, Hideo; Sata, Masataka; Sugimura, Haruhiko; Sugiyama, Yuichi; Toi, Masakazu; Irimura, Tatsuro.

In: Cancer Science, Vol. 107, No. 2, 01.02.2016, p. 189-202.

Research output: Contribution to journalArticle

Hayakawa, Y, Kawada, M, Nishikawa, H, Ochiya, T, Saya, H, Seimiya, H, Yao, R, Hayashi, M, Kai, C, Matsuda, A, Naoe, T, Ohtsu, A, Okazaki, T, Saji, H, Sata, M, Sugimura, H, Sugiyama, Y, Toi, M & Irimura, T 2016, 'Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs', Cancer Science, vol. 107, no. 2, pp. 189-202. https://doi.org/10.1111/cas.12857
Hayakawa, Yoshihiro ; Kawada, Manabu ; Nishikawa, Hiroyoshi ; Ochiya, Takahiro ; Saya, Hideyuki ; Seimiya, Hiroyuki ; Yao, Ryoji ; Hayashi, Masahiro ; Kai, Chieko ; Matsuda, Akira ; Naoe, Tomoki ; Ohtsu, Atsushi ; Okazaki, Taku ; Saji, Hideo ; Sata, Masataka ; Sugimura, Haruhiko ; Sugiyama, Yuichi ; Toi, Masakazu ; Irimura, Tatsuro. / Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs. In: Cancer Science. 2016 ; Vol. 107, No. 2. pp. 189-202.
@article{0428d72d838c4f0b939d1ecdc14e4613,
title = "Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs",
abstract = "Non-clinical studies are necessary at each stage of the development of oncology drugs. Many experimental cancer models have been developed to investigate carcinogenesis, cancer progression, metastasis, and other aspects in cancer biology and these models turned out to be useful in the efficacy evaluation and the safety prediction of oncology drugs. While the diversity and the degree of engagement in genetic changes in the initiation of cancer cell growth and progression are widely accepted, it has become increasingly clear that the roles of host cells, tissue microenvironment, and the immune system also play important roles in cancer. Therefore, the methods used to develop oncology drugs should continuously be revised based on the advances in our understanding of cancer. In this review, we extensively summarize the effective use of those models, their advantages and disadvantages, ranges to be evaluated and limitations of the models currently used for the development and for the evaluation of oncology drugs. This review summarizes the effective use of animal models, their advantages and disadvantages, ranges to be evaluated and limitations of the models currently used for the development and for the evaluation of oncology drugs.",
keywords = "Animal model, Cancer, Drug development, Oncology drug, Regulatory science",
author = "Yoshihiro Hayakawa and Manabu Kawada and Hiroyoshi Nishikawa and Takahiro Ochiya and Hideyuki Saya and Hiroyuki Seimiya and Ryoji Yao and Masahiro Hayashi and Chieko Kai and Akira Matsuda and Tomoki Naoe and Atsushi Ohtsu and Taku Okazaki and Hideo Saji and Masataka Sata and Haruhiko Sugimura and Yuichi Sugiyama and Masakazu Toi and Tatsuro Irimura",
year = "2016",
month = "2",
day = "1",
doi = "10.1111/cas.12857",
language = "English",
volume = "107",
pages = "189--202",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs

AU - Hayakawa, Yoshihiro

AU - Kawada, Manabu

AU - Nishikawa, Hiroyoshi

AU - Ochiya, Takahiro

AU - Saya, Hideyuki

AU - Seimiya, Hiroyuki

AU - Yao, Ryoji

AU - Hayashi, Masahiro

AU - Kai, Chieko

AU - Matsuda, Akira

AU - Naoe, Tomoki

AU - Ohtsu, Atsushi

AU - Okazaki, Taku

AU - Saji, Hideo

AU - Sata, Masataka

AU - Sugimura, Haruhiko

AU - Sugiyama, Yuichi

AU - Toi, Masakazu

AU - Irimura, Tatsuro

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Non-clinical studies are necessary at each stage of the development of oncology drugs. Many experimental cancer models have been developed to investigate carcinogenesis, cancer progression, metastasis, and other aspects in cancer biology and these models turned out to be useful in the efficacy evaluation and the safety prediction of oncology drugs. While the diversity and the degree of engagement in genetic changes in the initiation of cancer cell growth and progression are widely accepted, it has become increasingly clear that the roles of host cells, tissue microenvironment, and the immune system also play important roles in cancer. Therefore, the methods used to develop oncology drugs should continuously be revised based on the advances in our understanding of cancer. In this review, we extensively summarize the effective use of those models, their advantages and disadvantages, ranges to be evaluated and limitations of the models currently used for the development and for the evaluation of oncology drugs. This review summarizes the effective use of animal models, their advantages and disadvantages, ranges to be evaluated and limitations of the models currently used for the development and for the evaluation of oncology drugs.

AB - Non-clinical studies are necessary at each stage of the development of oncology drugs. Many experimental cancer models have been developed to investigate carcinogenesis, cancer progression, metastasis, and other aspects in cancer biology and these models turned out to be useful in the efficacy evaluation and the safety prediction of oncology drugs. While the diversity and the degree of engagement in genetic changes in the initiation of cancer cell growth and progression are widely accepted, it has become increasingly clear that the roles of host cells, tissue microenvironment, and the immune system also play important roles in cancer. Therefore, the methods used to develop oncology drugs should continuously be revised based on the advances in our understanding of cancer. In this review, we extensively summarize the effective use of those models, their advantages and disadvantages, ranges to be evaluated and limitations of the models currently used for the development and for the evaluation of oncology drugs. This review summarizes the effective use of animal models, their advantages and disadvantages, ranges to be evaluated and limitations of the models currently used for the development and for the evaluation of oncology drugs.

KW - Animal model

KW - Cancer

KW - Drug development

KW - Oncology drug

KW - Regulatory science

UR - http://www.scopus.com/inward/record.url?scp=84959038257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959038257&partnerID=8YFLogxK

U2 - 10.1111/cas.12857

DO - 10.1111/cas.12857

M3 - Article

C2 - 26919617

AN - SCOPUS:84959038257

VL - 107

SP - 189

EP - 202

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 2

ER -